Sarcoidosis Small-Fiber Neuropathy
In a randomized, double-blind pilot study, ARA 290 improved small-fiber neuropathy symptom scores and physical functioning in sarcoidosis patients, with no safety concerns.
Heij et al. 2012≥99% Purity
ARA-290
An EPO-derived peptide studied for calming inflammation and nerve repair
$60.00$30.00/vial with BOGO
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
ARA-290 is also called cibinetide. It is a peptide made of 11 amino acids, taken from one section of erythropoietin. That is the hormone that drives red blood cell production. ARA-290 was designed to keep the tissue repair signaling while leaving out the red blood cell effect. Research has measured its activity at the innate repair receptor, a two-part receptor complex, and examined nerve and inflammation endpoints.
EPO helix-B surface derived 11-amino-acid peptide
- Formula
- C55H89N19O20
- Molecular weight
- 1257.3 g/mol
- Form
- Lyophilized powder
- CAS / ID
- 1208243-50-8
0
Amino Acids
EPO helix-B derived peptide
0
Molecular Weight (Da)
C55H89N19O20
0+
Human Trials
sarcoidosis small-fiber neuropathy
0
Research Areas
Sarcoidosis Small-Fiber Neuropathy · Corneal & Skin Nerve Fiber Regrowth · Long-Term Allodynia Relief & more
How It Works
How ARA-290 works
The pathways ARA-290 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
IRR (EPOR/CD131) Agonism
Innate Repair Receptor
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B surface of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) — a heterocomplex of the EPO receptor and the β-common receptor (CD131) — the tissue-protective arm of EPO signaling, without engaging the classical receptor that drives red-cell production.
- Selective IRR (EPOR/βcR) agonism
- Non-erythropoietic — no effect on hematocrit
- Mimics EPO's helix-B tissue-protective domain
Resolution of Inflammation
Anti-Inflammatory
Through the innate repair receptor, ARA-290 dampens pro-inflammatory signaling and promotes its resolution, reducing collateral tissue damage from the injury and immune response — a mechanism characterized in both preclinical and clinical research.
- Suppresses pro-inflammatory cytokine signaling
- Shifts macrophages toward a reparative phenotype
- Suppresses spinal microglial activation in pain models
Cytoprotective & Neuroregenerative Signaling
Tissue Protection
IRR activation engages JAK2/STAT3, PI3K/Akt, and anti-apoptotic Bcl-2-family pathways, supporting cell survival and small-nerve-fiber regeneration despite the peptide's very short plasma half-life.
- Activates JAK2/STAT3 & PI3K/Akt survival signaling
- Anti-apoptotic Bcl-2 family engagement
- Associated with small-fiber nerve regrowth in research
Uses & Applications
What ARA-290 is researched for
The main areas ARA-290 is being studied for — and the study-reported figures behind them.
Corneal & Skin Nerve Fiber Regrowth
28 days of ARA 290 significantly improved neuropathic symptoms and initiated regrowth of small nerve fibers, including increased corneal nerve fiber density.
Dahan et al. 2013Long-Term Allodynia Relief
In rodent models, ARA 290 dose-dependently reduced mechanical and cold allodynia for up to 20 weeks, coupled with suppression of the spinal microglia response.
Swartjes et al. 2014EPO-Derived Cytoprotection
ARA 290 was engineered from EPO's tertiary structure to deliver tissue-protective and anti-inflammatory effects via the innate repair receptor, without stimulating erythropoiesis.
Brines et al. 2008Molecular Structure
The ARA-290 molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C55H89N19O20
Third-Party Verified
Independently tested. Verifiably pure.
Every batch of ARA-290 is sent to an accredited independent laboratory before it ships. Here is what we screen for.
- HPLC Purity AnalysisConfirms the peptide is ≥99% pure
- Mass SpectrometryVerifies the exact molecular identity
- Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass
- Endotoxins (LAL)Bacterial endotoxin levels — Pass
- Sterility TestingNo microbial contamination — Pass
- Net Peptide ContentActual peptide mass per vial verified
Certificate of Analysis · Freedom DiagnosticPASS
- HPLC Purity
- ≥99%
- Identity
- Mass-spec confirmed
- Endotoxin (LAL)
- Pass
- Net content
- Verified
Compound Information
Full specification
| Chemical Name | ARA-290 (Cibinetide) |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa) |
| Molecular Weight | 1,257.3 Da |
| Molecular Formula | C₅₅H₈₉N₁₉O₂₀ |
| CAS Number | 1208243-50-8 |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Sterile or bacteriostatic water |
| COA | Included with every order |
FAQ
Common questions about ARA-290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide engineered from the helix-B surface domain of erythropoietin (EPO). It was designed to activate EPO's tissue-protective, anti-inflammatory signaling through the innate repair receptor — without the red-blood-cell-stimulating activity of native EPO.
The IRR is a heterocomplex of the EPO receptor and the β-common receptor (CD131). It mediates EPO's protective and regenerative effects in tissue, distinct from the classical homodimeric EPO receptor that controls erythropoiesis. ARA-290 selectively activates this repair receptor.
No. ARA-290 is non-erythropoietic — it does not engage the receptor pathway that drives red-cell production, so it does not raise hematocrit. That separation of tissue protection from erythropoiesis is the central rationale behind its design.
Phase 2 studies in sarcoidosis-associated small-fiber neuropathy reported improved neuropathic symptom scores, increased corneal nerve fiber density, and regrowth of small nerve fibers, with a favorable safety profile. Preclinical models also show long-term reduction of neuropathic pain behaviors.
No. Research-grade ARA-290 sold here is strictly for in vitro laboratory research and analytical applications. It is not a drug and is not intended for human or veterinary use, consumption, or any clinical application.
Published Literature
Cited Sources
Peer-reviewed literature
Independent published research indexed from PubMed and peer-reviewed journals — not Eon Peptides claims.
[1]
PubMed
[2]Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
View source PubMed
[3]Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
View source PubMed
[4]ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
View source PubMed
ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response
View source For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.